查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886323

BETA受體阻斷劑市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、適應症、藥物、配銷通路、應用、地區和競爭格局分類，2020-2030年預測

Beta blockers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By Drugs, By Distribution Channel, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球BETA受體阻斷劑市場規模為99.4億美元，預計2030年將以5.95%的複合年成長率成長至140.6億美元。 BETA受體阻斷劑是一類藥物，其作用機轉是透過抑制腎上腺素（也稱為腎上腺素）對心臟和血管的影響。這種作用可降低心率和心肌收縮力，進而降低血壓並改善血流。全球BETA受體阻斷劑市場的主要促進因素是心血管疾病（包括高血壓、心絞痛和心律不整）盛行率的上升，以及老年人口的不斷成長，而老年人本身就更容易患上這些疾病。

市場概覽
預測期 2026-2030
市場規模：2024年 99.4億美元
市場規模：2030年 140.6億美元
複合年成長率：2025-2030年 5.95%
成長最快的細分市場 心絞痛
最大的市場 北美洲

主要市場促進因素

心血管疾病負擔日益加重是全球BETA受體阻斷劑市場的主要促進因素。這些疾病包括高血壓、心絞痛和各種心律不整，需要採取治療介入措施來控制症狀和預防疾病進展。

主要市場挑戰

主要品牌BETA受體阻斷劑專利到期對全球市場成長構成重大挑戰。專利保護期結束後，學名藥生產商會推出生物等效版本，加劇價格競爭，並導致市場飽和。

主要市場趨勢

全球BETA受體阻斷劑市場受到藥物遞送系統不斷改進和治療效果提升的顯著影響。這一趨勢涵蓋了新型製劑和新一代藥物，旨在透過最佳化藥物動力學和減少副作用來改善患者療效。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球BETA受體阻斷劑市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（非選擇性試劑、選擇性試劑）
    • 依適應症（心絞痛、心臟衰竭、高血壓、其他）
    • 依藥物分類（倍他洛爾、醋丁洛爾、艾司洛爾、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 依應用領域（心臟病、高血壓、青光眼、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美BETA受體阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲BETA受體阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區BETA受體阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲BETA受體阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲BETA受體阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球BETA受體阻斷劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Pfizer Inc
  • Novartis AG
  • Merck & Co. Inc
  • AstraZeneca PLC
  • Johnson and Johnson Services, Inc.
  • Eli Lilly and Company
  • Sanofi SA
  • Bristol-Myers Squibb
  • Bayer AG
  • GlaxoSmithKline plc

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22234

The Global Beta blockers Market, valued at USD 9.94 Billion in 2024, is projected to experience a CAGR of 5.95% to reach USD 14.06 Billion by 2030. Beta blockers represent a class of pharmaceutical agents that function by inhibiting the effects of epinephrine, also known as adrenaline, on the heart and blood vessels. This action results in a reduced heart rate and decreased force of cardiac contraction, thereby lowering blood pressure and enhancing blood flow. The global market for beta blockers is primarily driven by the rising prevalence of cardiovascular diseases, including hypertension, angina, and arrhythmias, coupled with an expanding geriatric population that is inherently more susceptible to such conditions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 9.94 Billion
Market Size 2030USD 14.06 Billion
CAGR 2025-20305.95%
Fastest Growing SegmentAngina Pectoris
Largest MarketNorth America

Key Market Drivers

The increasing burden of cardiovascular diseases represents a fundamental driver for the global beta blockers market. These conditions, encompassing hypertension, angina, and various arrhythmias, necessitate therapeutic interventions to manage symptoms and prevent disease progression. The continued rise in these diagnoses directly expands the patient pool requiring cardiac medications.

Key Market Challenges

The impact of patent expirations on key brand-name beta blockers poses a significant challenge to the growth of the global market. Upon the loss of patent exclusivity, generic manufacturers introduce bioequivalent versions, intensifying price competition and increasing market saturation. This dynamic typically results in a substantial decline in revenue for originator companies as market share shifts towards these lower-priced generic alternatives.

Key Market Trends

The global beta blockers market is significantly influenced by the continuous development of more sophisticated drug delivery systems and enhanced therapeutic profiles. This trend, encompassing both novel formulations and next-generation agents, aims to improve patient outcomes through optimized pharmacokinetics and reduced side effects. For instance, the United States Pharmacopeia announced on August 30, 2024, that four new dissolution tests were added to the Metoprolol Succinate Extended-Release Tablets monograph, reflecting ongoing FDA approvals of diverse extended-release formulations.

Key Market Players

  • Pfizer Inc
  • Novartis AG
  • Merck & Co. Inc
  • AstraZeneca PLC
  • Johnson and Johnson Services, Inc.
  • Eli Lilly and Company
  • Sanofi SA
  • Bristol-Myers Squibb
  • Bayer AG
  • GlaxoSmithKline plc

Report Scope:

In this report, the Global Beta blockers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Beta blockers Market, By Type:

  • Non-selective Agents
  • Selective Agents

Beta blockers Market, By Indications:

  • Angina Pectoris
  • Heart Failure
  • High Blood Pressure
  • Others

Beta blockers Market, By Drugs:

  • Betaxolol
  • Acebutolol
  • Esmolol
  • Others

Beta blockers Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Beta blockers Market, By Application:

  • Cardiac Diseases
  • Hypertension
  • Glaucoma
  • Others

Beta blockers Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Beta blockers Market.

Available Customizations:

Global Beta blockers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Beta blockers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Non-selective Agents, Selective Agents)
    • 5.2.2. By Indications (Angina Pectoris, Heart Failure, High Blood Pressure, Others)
    • 5.2.3. By Drugs (Betaxolol, Acebutolol, Esmolol, Others)
    • 5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.5. By Application (Cardiac Diseases, Hypertension, Glaucoma, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North America Beta blockers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Indications
    • 6.2.3. By Drugs
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Application
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Beta blockers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Indications
        • 6.3.1.2.3. By Drugs
        • 6.3.1.2.4. By Distribution Channel
        • 6.3.1.2.5. By Application
    • 6.3.2. Canada Beta blockers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Indications
        • 6.3.2.2.3. By Drugs
        • 6.3.2.2.4. By Distribution Channel
        • 6.3.2.2.5. By Application
    • 6.3.3. Mexico Beta blockers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Indications
        • 6.3.3.2.3. By Drugs
        • 6.3.3.2.4. By Distribution Channel
        • 6.3.3.2.5. By Application

7. Europe Beta blockers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Indications
    • 7.2.3. By Drugs
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Application
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Beta blockers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Indications
        • 7.3.1.2.3. By Drugs
        • 7.3.1.2.4. By Distribution Channel
        • 7.3.1.2.5. By Application
    • 7.3.2. France Beta blockers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Indications
        • 7.3.2.2.3. By Drugs
        • 7.3.2.2.4. By Distribution Channel
        • 7.3.2.2.5. By Application
    • 7.3.3. United Kingdom Beta blockers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Indications
        • 7.3.3.2.3. By Drugs
        • 7.3.3.2.4. By Distribution Channel
        • 7.3.3.2.5. By Application
    • 7.3.4. Italy Beta blockers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Indications
        • 7.3.4.2.3. By Drugs
        • 7.3.4.2.4. By Distribution Channel
        • 7.3.4.2.5. By Application
    • 7.3.5. Spain Beta blockers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Indications
        • 7.3.5.2.3. By Drugs
        • 7.3.5.2.4. By Distribution Channel
        • 7.3.5.2.5. By Application

8. Asia Pacific Beta blockers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Indications
    • 8.2.3. By Drugs
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Application
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Beta blockers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Indications
        • 8.3.1.2.3. By Drugs
        • 8.3.1.2.4. By Distribution Channel
        • 8.3.1.2.5. By Application
    • 8.3.2. India Beta blockers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Indications
        • 8.3.2.2.3. By Drugs
        • 8.3.2.2.4. By Distribution Channel
        • 8.3.2.2.5. By Application
    • 8.3.3. Japan Beta blockers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Indications
        • 8.3.3.2.3. By Drugs
        • 8.3.3.2.4. By Distribution Channel
        • 8.3.3.2.5. By Application
    • 8.3.4. South Korea Beta blockers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Indications
        • 8.3.4.2.3. By Drugs
        • 8.3.4.2.4. By Distribution Channel
        • 8.3.4.2.5. By Application
    • 8.3.5. Australia Beta blockers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Indications
        • 8.3.5.2.3. By Drugs
        • 8.3.5.2.4. By Distribution Channel
        • 8.3.5.2.5. By Application

9. Middle East & Africa Beta blockers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Indications
    • 9.2.3. By Drugs
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Application
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Beta blockers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Indications
        • 9.3.1.2.3. By Drugs
        • 9.3.1.2.4. By Distribution Channel
        • 9.3.1.2.5. By Application
    • 9.3.2. UAE Beta blockers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Indications
        • 9.3.2.2.3. By Drugs
        • 9.3.2.2.4. By Distribution Channel
        • 9.3.2.2.5. By Application
    • 9.3.3. South Africa Beta blockers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Indications
        • 9.3.3.2.3. By Drugs
        • 9.3.3.2.4. By Distribution Channel
        • 9.3.3.2.5. By Application

10. South America Beta blockers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Indications
    • 10.2.3. By Drugs
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Application
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Beta blockers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Indications
        • 10.3.1.2.3. By Drugs
        • 10.3.1.2.4. By Distribution Channel
        • 10.3.1.2.5. By Application
    • 10.3.2. Colombia Beta blockers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Indications
        • 10.3.2.2.3. By Drugs
        • 10.3.2.2.4. By Distribution Channel
        • 10.3.2.2.5. By Application
    • 10.3.3. Argentina Beta blockers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Indications
        • 10.3.3.2.3. By Drugs
        • 10.3.3.2.4. By Distribution Channel
        • 10.3.3.2.5. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Beta blockers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Merck & Co. Inc
  • 15.4. AstraZeneca PLC
  • 15.5. Johnson and Johnson Services, Inc.
  • 15.6. Eli Lilly and Company
  • 15.7. Sanofi SA
  • 15.8. Bristol-Myers Squibb
  • 15.9. Bayer AG
  • 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer